Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may detect a trigger event associated with a satellite communication link, the trigger event being based at least in part on at least one of: a status of an access link associated with the UE, or information associated with another device or a component of the UE. The UE may transmit a communication via the satellite communication link based at least in part on detecting the trigger event. Numerous other aspects are described.

Abstract: Provided is a tribenzazole amine derivative represented by Formula 1 that effectively absorbs high energy UV light from an external light source to minimize damage to organic materials present in an organic electroluminescent device, contributing to a substantial improvement in the lifetime of the organic electroluminescent device. Also provided is an organic electroluminescent device using the tribenzazole amine derivative. The organic electroluminescent device includes a first electrode, a second electrode, and an organic layer arranged between the first and second electrodes. The organic layer includes the tribenzazole amine derivative.

Abstract: Drug-delivery systems such as drug-delivery stents having an anti-proliferative agent such as everolimus and an anti-flammatory agent such as clobetasol are provided. Also disclosed are methods of treating a vascular impairment such as restenosis or vulnerable plaque.

Abstract: A drug-delivery system is provided including at least 100 ?g of everolimus and clobetasol, such that the ratio of everolimus to clobetasol is at least 10:1 (w/w) or the amount of everolimus by weight is at least 10 times more than clobetasol. The system can be a stent. Also provided a method of treating restenosis or vulnerable plaque of a blood vessel, the method includes locally administering to a patient a first drug selected from a group consisting of rapamycin (sirolimus), Biolimus A9, deforolimus, AP23572, tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40-O-(2-hydroxy)ethylrapamycin (everolimus), 40-O-(3-hydroxy)propylrapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethylrapamycin, 40-O-tetrazolylrapamycin and 40-epi-(N1-tetrazolyl)rapamycin, and locally administering to a patient a second drug consisting of clobetasol, wherein the minimum amount of the first drug that is locally administered is 100 ?g, and wherein the ratio of the first drug to the second drug is, for example, 10:1 to 100:1 (w/w).

Abstract: Drug-delivery stents capable of providing release of two or more drugs such as everolimus and estradiol are provided. The stents can be used for treating a disease such as restenosis and vulnerable plaque.

Abstract: A portable terminal and a method for displaying a preference item in the portable terminal that provides a distinguishing view of the preferential item(s). The method includes: displaying, upon receipt of a request to display an item list, the item list; checking, while searching the item list, whether a preference is set for an item to be displayed; and applying, if a preference is set for an item to be displayed, an event to the preference item and displaying the preference item. Applying an event to the preference item and displaying the preference item may include: determining the event that is set for the preference item, and applying the event to the preference item and displaying the preference item.

Abstract: A composite implantable device for promoting tissue ingrowth therein comprising a biodurable reticulated elastomeric matrix having a three-dimensional porous structure having a continueous network of interconnected and intercommunicating open pores and a support structure is disclosed. The support structure may be a polymeric surgical mesh comprising a plurality of intersecting one-dimensional reinforcement elements, wherein said mesh is affixed to a face of said first matrix. Methods of making and using the implantable device are also provided.

Abstract: A drug-delivery system is provided including at least 100 ?g of everolimus and clobetasol, such that the ratio of everolimus to clobetasol is at least 10:1 (w/w) or the amount of everolimus by weight is at least 10 times more than clobetasol. The system can be a stent. Also provided a method of treating restenosis or vulnerable plaque of a blood vessel, the method includes locally administering to a patient a first drug selected from a group consisting of rapamycin (sirolimus), Biolimus A9, deforolimus, AP23572, tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40-O-(2-hydroxy)ethylrapamycin (everolimus), 40-O-(3-hydroxy)propylrapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethylrapamycin, 40-O-tetrazolylrapamycin and 40-epi-(N1-tetrazolyl)rapamycin, and locally administering to a patient a second drug consisting of clobetasol, wherein the minimum amount of the first drug that is locally administered is 100 ?g, and wherein the ratio of the first drug to the second drug is, for example, 10:1 to 100:1 (w/w).

Abstract: A portable terminal and a method for displaying a preference item in the portable terminal that provides a distinguishing view of the preferential item(s). The method includes: displaying, upon receipt of a request to display an item list, the item list; checking, while searching the item list, whether a preference is set for an item to be displayed; and applying, if a preference is set for an item to be displayed, an event to the preference item and displaying the preference item. Applying an event to the preference item and displaying the preference item may include: determining the event that is set for the preference item, and applying the event to the preference item and displaying the preference item.

Abstract: An implantable medical device including a polymer matrix containing everolimus and pimecrolimus, and methods of using the device for the treatment of vascular disease are disclosed.

Abstract: Drug-delivery stents capable of providing release of two or more drugs such as everolimus and estradiol are provided. The stents can be used for treating a disease such as restenosis and vulnerable plaque.

Abstract: Drug-delivery systems such as drug-delivery stents having an anti-proliferative agent such as everolimus and an anti-flammatory agent such as clobetasol are provided. Also disclosed are methods of treating a vascular impairment such as restenosis or vulnerable plaque.

Abstract: Drug-delivery systems such as drug-delivery stents having an anti-proliferative agent such as everolimus and an anti-flammatory agent such as clobetasol are provided. Also disclosed are methods of treating a vascular impairment such as restenosis or vulnerable plaque.

Abstract: Drug-delivery stents capable of providing release of two or more drugs such as everolimus and estradiol are provided. The stents can be used for treating a disease such as restenosis and vulnerable plaque.

Abstract: A cleaning pad for use on a cleaning system in which cleaning fluid or other liquid is dispensed onto a surface in front of a cleaning head portion, the cleaning pad comprising a central absorbent and scrubbing portion, a back edge portion for removably attaching the cleaning pad to the cleaning head portion, and a front edge portion for removably attaching the cleaning pad to the cleaning head portion, the front edge portion having a notch thereon, thereby allowing attachment of the cleaning pad to the cleaning head portion such that cleaning or other fluid can be dispensed from the cleaning head portion onto a surface in front of the cleaning head portion without interference by the cleaning pad.

Abstract: A granular enzyme composition is produced having reduced tendency to form dust and leave a residue, and improved stability and delayed release characteristics. The composition has a core, optionally coated with a vinyl polymer, a layer containing an enzyme and a vinyl polymer and optionally a plasticizer or anti-agglomeration agent, and an outer coating containing a polymer and optionally a low residue pigment and/or lubricant. Preferably, the core is a salt or sugar nonpareil, the vinyl polymer coating the core is polyvinyl alcohol and most preferably partially hydrolyzed polyvinyl alcohol, the vinyl polymer in the enzyme layer is polyvinyl pyrrolidone, and the polymer of the outer coating is polyvinyl pyrrolidone, polyvinyl alcohol which may be partially hydrolyzed, polyethylene glycol or mixtures thereof such as a mixture of polyvinyl pyrrolidone and polyvinyl alcohol or a mixture of polyvinyl pyrrolidone and polyethylene glycol.